A randomized trial of aspirin to prevent colorectal adenomas.
By J. Baron, B. Cole, R. Sandler, R. Haile, D. Ahnen, R. Bresalier, G. McKeown-Eyssen, R. Summers, R. Rothstein, C. Burke and 14 more. New England Journal of Medicine, 2003
1,364 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Pharmacology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/80fb18ad12ee71bab7d1b4beda226cee9aa5ff3d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Hanchen Li
- Xueli Fan
- T. Warner
- D. Simmons
- J. Mitchell
- J. Houghton
- R. Botting
- T. Hla
Citations in the corpus
- Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic (2004, background): “(65); in another study, the standard dose was found to”
- Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition (2004, background): “…COX-1 inhibitor, has recently been shown in three randomized placebo-controlled trials to be “moderately effective” in preventing the appearance of sporadic colorectal adenomas in patients with a history of these tumors (Baron et al., 2003; Benamouzig et al., 2003; Sandler et al., 2003).”
- Tumor microenvironment: The role of the tumor stroma in cancer (2007, background): “NSAID use is associated with a decrease in the incidence of colorectal cancer [Sandler et al., 2003] and the precursor lesion, adenomas [Baron et al., 2003].”
- Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. (2012, neutral): “11,54–57 We believe there is insufficient evidence to recommend any change in surveillance intervals in patients who are taking these medications.”